On the stock market since 2021, it operates in the world of health and science. It has 782 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (-1% a year).
If every debt were paid off today, $2.2B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 6 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — still a thick cushion, though costs have been eating into it lately.
There is $2.3B in the vault; even if every debt were paid off, $2.2B would remain.
It pays out $0.04 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.65. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 4% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, BJTRF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BJTRF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.